Nasdaq

Orchestra BioMed Highlights Potential of AVIM Therapy for Managing Hypertension in High-Risk Patients at CSI 2025 Meeting

Orchestra BioMed Holdings, Inc. presented key insights on its atrioventricular interval modulation (AVIM) therapy for managing high-risk hypertension at the CSI 2025 Meeting. The therapy aims to ...
Nasdaq

Orchestra BioMed Presents Late-Breaking Data on AVIM Therapy's Impact on Diastolic Dysfunction in Hypertensive Patients at THT 2025 Conference

Orchestra BioMed Holdings, Inc. announced promising echocardiographic data regarding atrioventricular interval modulation (AVIM) therapy's impact on patients with diastolic dysfunction at the THT 2025 ...
Business Insider

Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on ...

NEW HOPE, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to ...